Tracing FDA's draft guidance on early-phase IND protocol recommendations for solid tumors is open for public comment through January 12, 2027 under docket FDA-2026-D-13432.×Refreshed 1 min ago
All24 hours
Vertical
- All verticals
- Space
- Energy
- Quantum
- Robotics
- Cybersecurity
- Biotechnology
- Defense Tech
- Artificial Intelligence
× Show allIn focus
Senate advances bipartisan energy permitting bill as Democrats split
The Senate advanced the Bipartisan American Affordability and Jobs Act (S. 5653) 73-25 on a procedural vote. Senate leaders said amendment votes and final passage could come the week of Nov. 16. House Democrats are divided on revising the bill now or waiting for next year's Congress, while tribes, environmental groups and Hakeem Jeffries oppose it and Trump and industry groups back it. · yesterday
Forces, money & more EnergyIn the News
One card per story, every outlet that covered it22h agoYahooBill Cassidy says Trump’s FDA pick faces uncertain committee voteSenate HELP Chair Bill Cassidy says he still has questions about FDA commissioner nominee Heidi Overton, leaving the outcome of Wednesday's committee vote uncertain.1 outlet9 linked 4d agoLos Angeles TimesFor peptide enthusiasts, a new HHS policy means party timeHHS's enforcement discretion policy lets pharmacies compound six unapproved peptides ahead of a final FDA rule, which critics say expands access without adequate safety or efficacy evidence.1 outletBiotech5 linked
On the Hill
Congress, the White House and agencies3Ahead
Monday, Jan 11
Recent
Friday, Oct 25
Wednesday, Nov 11
3d agoAgencyHealth and Human Services DepartmentFDA announced a draft guidance giving sponsors recommendations for early-phase IND protocols for solid tumor drugs and biologics, with comments due January 11, 2027.BiotechDetails5 linked
Nothing from this branch in view.
Times ET
Contracts
Solicitations, SBIR topics, grants and awards1GrantNational Institutes of HealthOct 20NIH seeks applications for consortium Translational Centers using Microphysiological Systems for Infectious Diseases (RFA-AI-28-012), with a $7M ceiling.$7M ceilingCloses in 75 daysRFA-AI-28-012BiotechLifecycle14 linked